Association between immune-related adverse events and the prognosis of patients with gastric cancer treated with nivolumab: a meta-analysis.

ABSTRACT:

Background

Nivolumab is an effective treatment option for advanced gastric cancer (GC). This study aimed to conduct a systematic review of existing literature to investigate the relationship between immune-related adverse events (irAEs) and the prognosis of patients with GC treated with nivolumab.

Methods

We comprehensively searched four online literature databases: the Cochrane Central Register of Controlled Trials, PubMed, Embase, Web of Science, until 27 March 2024. The outcome measures of interest included: overall survival (OS), progression-free survival (PFS), hazard ratio (HR), median survival ratio (MSR), objective response rate (ORR), and disease control rate (DCR).

Results

A total of six studies, including 393 patients, met the eligibility criteria. The OS (

SUBMITTER: Zhang YJ 

PROVIDER: S-EPMC11410568 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature